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David Spoerl*, Yves-Marie Pers and Christian JorgensenAbstract
Background: Anti-neutrophil cytoplasmic antibodies are typically detected in anti-neutrophil cytoplasmic antibody
associated vasculitis, but are also present in a number of chronic inflammatory non-vasculitic conditions like
rheumatoid arthritis. Rare cases of granulomatosis with polyangiitis (formerly known as Wegener’s granulomatosis, a
vasculitic disorder frequently associated with the presence of anti-neutrophil cytoplasmic antibodies) in patients
with rheumatoid arthritis have been described in literature.
Case presentation: We report two middle-aged female patients with rheumatoid arthritis who developed
anti-neutrophil cytoplasmic antibodies and symptoms reminiscent of granulomatosis with polyangiitis. Despite the
lack of antibodies specific for proteinase 3 and the absence of a classical histology, we report a probable case of
granulomatosis with polyangiitis in the first patient, and consider rheumatoid vasculitis in the second patient.
Conclusion: Taken together with previous reports, these cases highlight that anti-neutrophil cytoplasmic antibodies
have to be evaluated very carefully in patients with rheumatoid arthritis. In this context, anti-neutrophil cytoplasmic
antibodies detected by indirect immunofluorescence appear to have a low diagnostic value for granulomatosis
with polyangiitis. Instead they may have prognostic value for assessing the course of rheumatoid arthritis.
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Rheumatoid arthritis (RA) is a systemic inflammatory
autoimmune disease characterized by chronic polyarthri-
tis, eventually leading to joint erosion, and by the pre-
sence of various autoantibodies. The autoantigens
recognized by these autoantibodies include cartilage
components, chaperones, nuclear proteins, citrullinated
proteins and enzymes. Anti-neutrophil cytoplasmic
antibodies (ANCA) are present in a number of chronic
inflammatory non-vasculitic conditions including RA
and are therefore considered of low diagnostic value in
this setting. In contrast, autoantibodies to proteinase 3
(PR3) are extremely useful as a diagnostic and disease
activity indicator in granulomatosis with polyangiitis
(GPA).* Correspondence: dspoerl@postmail.ch
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reproduction in any medium, provided the orWe report two patients with RA, as defined by the
American College of Rheumatology (ACR) criteria, who
developed ANCA and symptoms reminiscent of GPA,
but displayed only ambiguous histology for GPA. In this
context we discuss the value of ANCA as a diagnostic
and prognostic tool.Case presentation
Case presentation 1
A 53-years old female patient presented with erosive,
seropositive, anti-cyclic citrullinated protein antibody
(ACPA) positive RA in 1993. In 1999 she had an episode
of auricular chondritis and in 2003 a pericarditis. In
2007 she presented with arthralgia, rectorrhagia and
abdominal pain. Necrotizing intestinal vasculitis was
diagnosed after intestinal resection. The histological
findings, her history, plus the presence of chronic sinus-
itis and a four millimetres nodule at the left superiorLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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together with the presence of ANCA at 1:800 with peri-
nuclear (p-ANCA) pattern was reminiscent of GPA and
the patient was addressed to our clinic. The feasibility of
a lung biopsy has been discussed, but because of the size
of the nodule and the already known intestinal vasculitis,
this option has been rejected. Despite the lack of ANCA
specificity for either PR3 or myeloperoxidase (MPO) and
the absence of a classical histology, a diagnosis of GPA
was made and treatment with monthly intravenous 1.2g
cyclophosphamide was started. After two months her
arthralgia and abdominal pain improved, the pulmonary
nodule resolved and treatment was discontinued after
four months. In 2009 a bilateral meatomy was per-
formed for her recurrent sinusitis. There were no signs
of vasculitis and no granulomas in the collected tissues.
Rituximab and abatacept showed no efficacy on her
polyarthritis and the treatment was changed to tocilizu-
mab in 2010. Since then she continues to have mild ac-
tive GPA with recurrent sinusitis and chondritis butTable 1 Initial presentation and autoantibodies in case 1 and
Case 1
Initial symptoms Arthralgia, abdominal pain, cough, facial tenderness.
Initial clinical
findings
Four tender and swollen finger joints (not better desc
axillary lymphadenopathy left, tenderness in the left ili
No signs of neuropathy.
Histology Necrotizing vasculitis in tissue from the intestinal resec




CRP, ESR, cell counts and creatinine: within normal ran
immunoelectrophoresis with modest





ANA 1:160, Anti-dsDNA negative, Anti-ENA negative, R




Abdominal scan: absence of lymphadenopathy, no sig
diverticulitis.
Chest scan: 4mm nodule superior lobe left.
Sinus scan: signs of chronic maxillary bilateral sinusitis.
Treatments Prior to 2007: Gold salt, Mycophenolate mofetil, Etane
MTX.
4/2007: Cyclophosphamide




MCP: metacarpophalangeal, CRP: C-reactive protein, ESR: erythrocyte sedimentation
Extractable nuclear antigen, ANCA: anti-neutrophil cytoplasmic antibodies (Titre), PR
antibody, RF: rheumatoid factor, MTX: Methotrexate, Ig: Immunoglobulin.shows no other organ involvement and her RA is in re-
mission (Table 1).
Case presentation 2
A 40-years old female patient presented with new onset
of inflammatory, unclassified polyarthritis in 2000.
Rheumatoid factor (RF) was positive, ACPA negative. In
2001 computer tomography showed four pulmonary
nodules. Transbronchial biopsy revealed a lymphogranu-
locytic infiltrate, without signs of vasculitis. Transthoracic
biopsy of a subpleural nodule showed a lymphohistiocytic
infiltrate with central fibrinoid necrosis, but no granu-
loma. ANCA with cytoplasmic (c-ANCA) pattern, but no
antigen specificity, were increased at 1:500. A diagnosis
of GPA was made irrespective of the absence of upper
airway or renal disease. Azathioprine and later cyclophos-
phamide treatments were introduced to control GPA
with radiological (resolution of pulmonary nodules) but
no clinical (arthralgia) efficacy. Infliximab allowed even-
tual reduction of concomitant corticosteroid treatment.2
Case 2




Tender right 3rd MCP joint and right shoulder, erythema right
lower limb. No signs of neuropathy.
tion. No
sinus
Transthoracic biopsy: lymphohistiocytic infiltrate with central
fibrinoid necrosis, no granulomas. Transbronchial biopsy:
lymphogranulocytic infiltrate, no signs of vasculitis.
ge, ESR 24mm, leucocytes 3000/mm3, CRP 20mg/l (<5), creatinine,
C3, C4 within normal range, normal immunoelectrophoresis,




ANA 1:320, Anti-dsDNA 75U/ml (<55), Anti-ENA negative, RF
63U/ml (<15), ACPA negative, ANCA 1:500, Anti-PR3 negative,
Anti-MPO negative, lupus anticoagulant antibodies negative.
ns of Radiography: normal skeletal imaging of hands and feet,
normal chest radiography.
Schirmer Test negative.
Salivary gland biopsy: modest lymphocytic infiltration (Focus
score <1).
Lung function: signs of obstruction.
Computer tomography: four pulmonary nodules.






rate ANA: antinuclear antibody (Titre), dsDNA: double-stranded DNA, ENA:
3: proteinase 3, MPO: myeloperoxidase, ACPA: Anti-cyclic citrullinated protein
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ered to have RA with a concomitant history of GPA.
Treatment with etanercept showed no benefit while
rituximab, started in 2004 and continued twice yearly, led
to long lasting remission of RA and quiescent GPA
(Table 1).
Discussion
Eleven cases of GPA in patients with RA have been
reported in literature since 1970, four of which displayed
ANCA specific for PR3 [1-8]. Four patients with ANCA
associated vasculitis (AAV) fulfilling the ACR criteria for
RA were described in 2010, but because no destructive
arthritis could be detected radiologically they were not
considered to have concomitant RA [9].
It has been suggested that both RA and GPA may arise
from a similar genetic predisposition. The PTPN22
620W functional polymorphism has been implicated in
the pathogenesis of GPA and RA [10]. More recently, a
meta-analysis yielded a statistically significant associ-
ation between GPA and the rs3087243 gene polymorph-
ism in Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4)
[11], also known to enhance the development of ACPA-
positive RA as compared with ACPA-negative RA [12].
RA is complicated by rheumatoid vasculitis (RV) in
approximately 1-5% of patients. RV is a systemic necro-
tizing vasculitis affecting small and medium-sized ves-
sels. RV commonly presents in seropositive patients with
multiple erosions and a long lasting history of RA. It is
characterized histopathologically in the acute stages by
fibrinoid necrosis with an inflammatory infiltrate, and in
chronic cases by vessel wall fibrosis, occlusion and reca-
nalization. Clinical features of RV include Raynaud's
phenomenon, digital infarcts, skin ulceration and mono-
neuritis multiplex. Cutaneous vasculitis, multifocal neur-
opathy, and depressed complement levels are all
indicators of poor prognosis [13]. Clinically apparent
RV of the gastrointestinal tract is rare, but often cata-
strophic, resulting in ischemic ulcers and bowel infarc-
tion [14]. In addition to RA duration, other risk factors
for RV include the presence of extra-articular manifesta-
tions of RA, specifically rheumatoid nodulosis, scleritis,
amyloidosis, and the presence of RF and ACPA
[15]. Both RV and GPA can present with symmetrical
peripheral polyarthritis. Gastrointestinal involvement
occurs in approximately 1-10% in both diseases [16].
Other authors report an incidence of up to 38% in RV
patients [14].
ANCA are not included in the ACR classification
criteria or Chapel Hill Consensus Conference (CHCC)
definitions for AAV, but their testing in the ap-
propriate clinical context is recommended [17,18].
There are 2 main techniques used to test for ANCA,
indirect immunofluorescence (IIF) and enzyme- linkedimmunosorbent assay (ELISA). IIF can demonstrate a
perinuclear, a cytoplasmic or an atypical staining pattern
[19]. These patterns reflect the staining of antigenic pro-
teins, but are not antigen specific. While c-ANCA pat-
tern is frequently due to a specific serine PR3, p-ANCA
pattern can result from the presence of a number of dif-
ferent minor antigens. Positive ANCA test results have
been reported in a number of rheumatic conditions, in-
cluding RA, and high titres of antinuclear antibodies
(ANA) can be confused for a p-ANCA, especially in sys-
temic lupus erythematosus where high titres of these
antibodies are found [19,20]. The use of cell fixatives
other than ethanol, e.g., formalin and methanol, has
been reported to allow differentiation of ANCA and
ANA in these cases [21].
Studies of RA cohorts showed that around 16–52% of
patients were ANCA positive in IIF and 3–32% in ELISA
assays [9]. Up to 21 to 36% of RA patients may have an
associated p-ANCA or atypical ANCA pattern in IIF
and up to 10% of patients have anti-MPO antibodies as
demonstrated by ELISA testing [22,23]. In a study inves-
tigating sera from RA patients, 49% had p-ANCA in IIF.
Among these patients, 91% showed a specific immunos-
taining upon examination at higher magnification that
did not correspond to "true" ANCA but to antibodies
directed against nuclear or perinuclear antigenic consti-
tuents of the neutrophils [24]. In RV, up to 48% of
patients show positive p-ANCA, a few (4-11%) being
positive for anti-PR3 or anti-MPO [25].
In a multi-centre study, IIF had a sensitivity of 85%
and a specificity of 76% for detecting GPA. The relatively
low specificity was mainly due to positive p-ANCA in
disease controls that included 7 patients with RV (one
had positive p-ANCA) [26]. Conversely, the sensitivity of
anti-PR3 antibodies for patients with GPA was 65 to
67%. This sensitivity was similar in patients with classical
histology (granulomas) as compared to those with clin-
ical characteristics of GPA, but who only displayed
histological evidence of vasculitis or crescentic nephritis
without granulomas. In this study, the specificity of anti-
PR3 antibodies alone for “idiopathic systemic vasculitis”
(mainly AAV) was 86-89% towards disease controls. The
specificity was improved to 99% if anti-PR3 antibodies
were found in combination with c-ANCA [26].
In a Japanese cohort, 16% of 125 RA patients were posi-
tive for ANCA against minor antigens of unknown signifi-
cance. In this study, ANCA positive patients had a higher
joint score and an elevated erythrocyte sedimentation rate
(ESR), compared to those who were ANCA negative, but
signs of vasculitis were not more frequent [27]. Other
authors found that these ANCA-ACPA double positive
RA patients may more frequently present with lung
nodules and have erosive lesions of greater severity com-
pared to ANCA negative RA patients, but it is uncertain if
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Moreover, p-ANCA positivity in RA has been found to be
an independent predictor of RA-‐associated nephropathy
[23] and, in early RA, predicted rapid radiographic joint
destruction [28]. Other groups found no significant associ-
ation between ANCA positivity and clinical, biological,
and radiological disease activity assessments in RA [29].
Rather, ANCA positivity appeared to be associated with
previous intake of sulphasalazine [30].
Finally, while RF can be detected in up to 37–50% of
AAV patients without any prognostic value, ACPA de-
velop in 1-2% of AAV patients. AAV patients with ACPA
seem to have more severe vasculitis manifestations and
unusual remittent joint manifestations, but do not de-
velop erosive lesions, therefore excluding a simple over-
lap with RA [9].Conclusions
IIF in our patients has been performed in ethanol fixed
cells, but because ANA were found only in low titres
compared to ANCA (especially during follow up), false
positive results are unlikely. Retrospectively, case 1 had
erosive RA, showed histological evidence of vasculitis
and clinical findings were indeed suggestive of con-
comitant GPA, but RV cannot be excluded. Auricular
chondritis was suggestive for relapsing polychondritis,
but the patient did not fulfil the diagnostic criteria for
this disease [31].
ACPA are highly specific for RA [32]. Case 2 deve-
loped ACPA only three years after the onset of polyar-
thritis. While about 40% of RA patients develop these
antibodies before the onset of articular symptoms, some
patients become positive only throughout the course of
their disease and some will remain ACPA negative
[32,33]. Case 2 probably only had ACPA positive RA
with pulmonary nodules, but GPA and RV are possible
alternative diagnosis. RV appears less probable because
of the short history of RA and the lack of erosions in
this patient.
These two cases highlight the difficulty in differentia-
ting extra-articular RA, RV and GPA in RA patients who
present with signs of AAV. Most biopsies from the
upper respiratory tract and the gastrointestinal tract do
not show classical granulomas in GPA [16,34] and can-
not confirm this diagnosis. Testing for ANCA may be
helpful in discriminating RV and GPA, but results have
to be evaluated with caution in RA. Positive ANCA spe-
cific for PR3 or MPO in ELISA have a high specificity
for AAV, and therefore a high diagnostic value. However,
because GPA in RA is rare, the corresponding positive
predictive value of ANCA in this setting remains low.
In contrast, ANCA positivity in IIF has been shown
to have a prognostic value for the course of early RA,by predicting a rapid joint destruction and a higher in-
flammatory activity, but has a low diagnostic value.
Only one of our patients developed erosive disease, but
both had a high inflammatory activity, demonstrated by
the different drugs that were needed in order to achieve
disease remission.
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